Upstate discovery advances understanding of inflammatory bowel disease
Upstate Medical University News Nov 04, 2017
Findings from a study into CrohnÂs disease, led by William G. Kerr, PhD, of Upstate Medical University, and his collaborators at the Erasmus Medical Center in the Netherlands, provide the first evidence that patients with debilitating inflammatory bowel disease lack sufficient quantities of a protein that comes from the SHIP1 gene. There is currently no cure for inflammatory bowel disease (IBD).
This finding could help guide doctors to determine how to treat patients with CrohnÂs disease. A simple blood test that detects the level of SHIP1 protein can tell the physician whether they should take a Âwait and see versus aggressive approach towards treatment, such as as TNF-alpha blocking antibodies like Humira. The findings also give a biological marker for the disease that could possibly lead to an earlier intervention before the disease manifests.
The article titled, ÂAnalysis of SHIP1 expression and activity in CrohnÂs disease, was published in the journal PLOS One.
Kerr discovered the link between SHIP1 deficiency and CrohnÂs disease in 2011. The next step for him and his colleagues is to investigate further why the expression of the SHIP gene is altered in CrohnÂs disease.
ÂWe followed a larger cohort of individuals with CrohnÂs disease in our second study and again found that SHIP1 expression is absent or drastically reduced in a subset of CrohnÂs disease and ulcerative colitis patients, said Kerr, an Empire Scholar, the Murphy Family Professor of Childrens Oncology Research, and professor of biochemistry and molecular biology, pediatrics and microbiology and immunology at Upstate. ÂWe are continuing our efforts to determine the molecular and genetic basis for this defectÂ.
He said that once researchers gain a better understanding of this problem with SHIP 1 expression in IBD patients, they will then attempt to model potential treatments for these patients by the use of small molecules that can Âturn up SHIP1 activity in these patients to levels that are beneficial and could prevent gastrointestinal inflammation. KerrÂs group, in collaboration with Dr. John Chisholm, has recently discovered such a molecule, called a SHIP1 agonist.
KerrÂs foray into CrohnÂs disease was catalyzed in 2011 by his finding that mutation of SHIP1 in mice triggered CrohnÂs-like disease in the small intestine of the mutant mice. He and his team then developed specialized assays to see if these findings translated to humans as well. In addition, they also used exome sequencing and RNAseqÂsequencing directly targeted to the SHIP1 geneÂto examine the structure of the SHIP1 gene at both the DNA and the RNA level.
Go to Original
This finding could help guide doctors to determine how to treat patients with CrohnÂs disease. A simple blood test that detects the level of SHIP1 protein can tell the physician whether they should take a Âwait and see versus aggressive approach towards treatment, such as as TNF-alpha blocking antibodies like Humira. The findings also give a biological marker for the disease that could possibly lead to an earlier intervention before the disease manifests.
The article titled, ÂAnalysis of SHIP1 expression and activity in CrohnÂs disease, was published in the journal PLOS One.
Kerr discovered the link between SHIP1 deficiency and CrohnÂs disease in 2011. The next step for him and his colleagues is to investigate further why the expression of the SHIP gene is altered in CrohnÂs disease.
ÂWe followed a larger cohort of individuals with CrohnÂs disease in our second study and again found that SHIP1 expression is absent or drastically reduced in a subset of CrohnÂs disease and ulcerative colitis patients, said Kerr, an Empire Scholar, the Murphy Family Professor of Childrens Oncology Research, and professor of biochemistry and molecular biology, pediatrics and microbiology and immunology at Upstate. ÂWe are continuing our efforts to determine the molecular and genetic basis for this defectÂ.
He said that once researchers gain a better understanding of this problem with SHIP 1 expression in IBD patients, they will then attempt to model potential treatments for these patients by the use of small molecules that can Âturn up SHIP1 activity in these patients to levels that are beneficial and could prevent gastrointestinal inflammation. KerrÂs group, in collaboration with Dr. John Chisholm, has recently discovered such a molecule, called a SHIP1 agonist.
KerrÂs foray into CrohnÂs disease was catalyzed in 2011 by his finding that mutation of SHIP1 in mice triggered CrohnÂs-like disease in the small intestine of the mutant mice. He and his team then developed specialized assays to see if these findings translated to humans as well. In addition, they also used exome sequencing and RNAseqÂsequencing directly targeted to the SHIP1 geneÂto examine the structure of the SHIP1 gene at both the DNA and the RNA level.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries